A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

Trial Details

NCT ID
NCT04669171
Phase
PHASE1 / PHASE2
Sponsor
Enterome
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • EO2463
  • lenalidomide
  • rituximab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Rochester, New York, United States|43.15478,-77.61556
  • Seattle, Washington, United States|47.60621,-122.33207
  • Amiens, France|49.9,2.3

Key Eligibility Criteria

  • For inclusion in Cohorts 1 and 4 patients should have relapsed/refractory, biopsy-proven grade 1, 2 or 3A, FL or MZL, ECOG performance status 0 to …
  • For inclusion in Cohort 2 patients should have newly diagnosed, previously untreated (radiotherapy as only prior treatment is allowed), biopsy-prov…
  • For inclusion in Cohort 3 patients should have newly diagnosed, previously untreated (radiotherapy as only prior treatment is allowed), biopsy-prov…
  • Patients with an age ≥ 18 years old.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →